Sugi Predict

Sugi Predict / Targets / DDOST

DDOST

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit · P39656 · DDOST on Sugi Atlas →

71 patent compounds predicted against DDOST, 11 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19532452 SCHEMBL19532452 0.42 3/20
SCHEMBL21504113 SCHEMBL21504113 0.35 3/20
SCHEMBL31345156 SCHEMBL31345156 0.41 2/20
SCHEMBL17992318 SCHEMBL17992318 0.39 2/20
SCHEMBL17882086 SCHEMBL17882086 0.35 2/20
SCHEMBL26181836 SCHEMBL26181836 0.35 2/20
SCHEMBL17992345 SCHEMBL17992345 0.33 2/20
SCHEMBL21335162 SCHEMBL21335162 0.32 2/20
SCHEMBL21335171 SCHEMBL21335171 0.32 2/20
SCHEMBL22105936 SCHEMBL22105936 0.31 2/20
SCHEMBL18712623 SCHEMBL18712623 0.48 1/20

Clinical trials — most relevant to DDOST by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose PHASE4COMPLETED
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes PHASE3COMPLETED
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment PHASE2/PHASE3COMPLETED
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy PHASE2UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity PHASE2COMPLETED
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines PHASE2COMPLETED
GD2/CD70 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Prebiotics in the Prevention of Necrotizing Enterocolitis PHASE2UNKNOWN
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® PHASE2COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers PHASE1UNKNOWN
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC PHASE1WITHDRAWN
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer PHASE1COMPLETED
A Study of Single Dose of LP-003 in Healthy Adult Subjects PHASE1ACTIVE_NOT_RECRUITING
Evaluation of GM101 Injection in Patients With Parkinson's Disease EARLY_PHASE1RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function nanCOMPLETED
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta nanRECRUITING
Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients nanUNKNOWN
Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health nanCOMPLETED
Fiber Fermentation Kinetics Inside the Gut, and Utilization of Bacterial Metabolites nanCOMPLETED
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DDOST binder may also engage these)

ProteinNameSimilarity
Q5R501 — 1.000 Q5R501 →
Q05052 — 1.000 Q05052 →
Q29381 — 1.000 Q29381 →
A6QPY0 — 1.000 A6QPY0 →
O54734 — 1.000 O54734 →
Q641Y0 — 0.996 Q641Y0 →
B1H3C9 — 0.995 B1H3C9 →
Q6GNR9 — 0.994 Q6GNR9 →
P48440 — 0.992 P48440 →
Q6NYS8 — 0.988 Q6NYS8 →
Q6GQK9 — 0.962 Q6GQK9 →
Q5U4X8 — 0.960 Q5U4X8 →
Q9EQH7 — 0.960 Q9EQH7 →
Q4R4U1 — 0.959 Q4R4U1 →
Q5SWU9 — 0.957 Q5SWU9 →
Q923S8 — 0.956 Q923S8 →
ACACA Acetyl-CoA carboxylase 1 0.956 landscape →
Q5R5F8 — 0.955 Q5R5F8 →
TPP2 Tripeptidyl-peptidase 2 0.954 landscape →
Q8K2G4 — 0.953 Q8K2G4 →
Q02353 — 0.953 Q02353 →
Q6P1X5 — 0.953 Q6P1X5 →
Q80YV4 — 0.952 Q80YV4 →
D2XV59 — 0.952 D2XV59 →
Q9EQW8 — 0.952 Q9EQW8 →
Q5ZIT8 — 0.952 Q5ZIT8 →
Q9H3R1 — 0.951 Q9H3R1 →
Q5XIK2 — 0.951 Q5XIK2 →
Q9NVE7 — 0.951 Q9NVE7 →
O95803 — 0.951 O95803 →